Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Share News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.175
Bid: 0.17
Ask: 0.18
Change: 0.00 (0.00%)
Spread: 0.01 (5.882%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 0.175
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK EXECUTIVE CHANGE SUMMARY: Ocean Wilson Long-Time Finance Head Exits

Tue, 24th Nov 2020 16:27

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Tuesday and not separately reported by Alliance News:

----------

Ocean Wilsons Holdings Ltd - Bermuda-based investment company operating a maritime services company in Brazil - Keith Middleton will retire as finance director on March 26 next year, after 25 years with the company. As a replacement, hires Leslie Rans as chief operating & financial officer from January 1. Rans was chief executive officer of both Digicel Bermuda and BAS Ltd. Additionally, Colin Maltby will retire as independent non-executive director on January 1 after eight years on the board.

----------

Trafalgar Property Group PLC - residential and assisted living property developer - Hires Gary Thorneycroft as financial director and board member, effective immediately. Thorneycroft was co-founder & CFO of Jones Food Co Ltd, which operates a vertical farm and was bought by online grocer Ocado Group PLC in 2019.

----------

Kore Potash PLC - potash development in Republic of Congo - Appoints Trinidad Maria Reyes Perez as non-executive director, nominated by shareholder Sociedad Quimica y Minera de Chile SA, effective immediately. She replaces Jose Antonio Merino, who has resigned immediately.

----------

InnovaDerma PLC - London-based beauty, personal care and life science products - Hires Simon Pyper as non-executive director, effective from end of general meeting on December 16. Rodney Turner will step down as non-executive director at the same time after serving since 2014. Pyper was CEO of digital market firm Be Heard Group PLC, a former AIM listing.

----------

Pacific Horizon Investment Trust PLC - invests in Asia-Pacific region excluding Japan and Indian sub-continent - Hires Robert Chote as non-executive director from Wednesday. Chote was chair of the UK government's Office for Budget Responsibility from 2010 to earlier this year.

----------

Open Orphan PLC - London-based contract research organisation and pharmaceutical services - Hires Curadh Pharmaceuticals Ltd CEO Elaine Sullivan as non-executive director. Sullivan also was a founder of Dublin-based Carrick Therapeutics. Mark Warne will step down as non-executive director on December 31. Warne was on the board of hVIVO PLC, acquired by Open Orphan at the start of 2020, and he helped with the integration.

----------

Nuformix PLC - London-based drug re-purposing specialist - Hires Julian Gilbert as non-executive director, effective immediately. Gilbert was co-founder & CEO of Acacia Pharma Group PLC.

----------

Alien Metals Ltd - Australia and Mexico focused minerals explorer - James Cable retires as non-executive director on Tuesday, ahead of the company annual general meeting on Wednesday. Cable was involved with the company from its inception.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
28 Jul 2022 16:14

EXECUTIVE CHANGES: Cohort co-founder out; Nuformix co-founder back

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Thursday and not separately reported by Alliance News:

Read more
28 Jul 2022 15:01

EARNINGS UPDATES: Alliance Trust beats benchmark and ups dividend

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
29 Jun 2022 12:25

IN BRIEF: Nuformix shares rise as progresses with cancer programme

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Starts to scale-up the production processes of lead cocrystals for its cancer programme NXP004, focused on the treatment for advanced ovarian cancer. Firm aims to develop new forms of Olaparib, "currently marketed by AstraZeneca PLC, under the Lynparza brand name," Nuformix explains. First approved in 2014 for advanced ovarian cancer, it has since received "similar approvals in breast, pancreatic and prostate cancers with further trials on-going."

Read more
27 Jun 2022 21:51

TRADING UPDATES: Anglo-Eastern Plantations sees palm oil prices rise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
31 May 2022 12:41

Nuformix Executive Chair Alastair Riddell resigns after one year

(Alliance News) - Nuformix PLC on Tuesday said Executive Chair Alastair Riddell has resigned with immediate effect.

Read more
30 May 2022 11:54

IN BRIEF: Nuformix shares plunge on inconsistent repeat study results

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Says the contract research organisation undertaking the final planned pre-clinical study for its NXP002 treatment had a protocol failure, which has voided the study. Says the organisation repeated the study and recorded results that were inconsistent with the first in vivo study at all time points and also with the oral control. Notes that no positive or negative conclusions could be drawn from this study.

Read more
30 May 2022 11:13

SMALL-CAP WINNERS & LOSERS: Foxtons finds new CEO; S4 revenue surges

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Monday.

Read more
28 Mar 2022 19:18

IN BRIEF: Nuformix NXP004 patent application reaches publication phase

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Says patent application for key asset NXP004 had progressed to the publication phase. NXP004 is a new formulation of Olaparib, which is used to treat ovarian, breast and pancreatic cancers currently marketed by FTSE 100-listed AstraZeneca PLC, under the name Lynparza. The patent application, which was made in September 2020, covers new olaparib oxalic acid cocrystals, their therapeutic uses and pharmaceutical compositions containing them. A second patent application was filed last November which remains pending.

Read more
8 Feb 2022 13:58

TRADING UPDATES: Round Hill Music buys Alice In Chains catalogue

TRADING UPDATES: Round Hill Music buys Alice In Chains catalogue

Read more
8 Feb 2022 10:52

SMALL-CAP WINNERS & LOSERS: Nuformix jumps as partner inks contract

SMALL-CAP WINNERS & LOSERS: Nuformix jumps as partner inks contract

Read more
14 Dec 2021 18:01

TRADING UPDATES: Cohort interim loss widens, Yourgene loss narrows

TRADING UPDATES: Cohort interim loss widens, Yourgene loss narrows

Read more
25 Nov 2021 16:23

IN BRIEF: Nuformix notes positive results for inhaled NXP002 dose

IN BRIEF: Nuformix notes positive results for inhaled NXP002 dose

Read more
12 Nov 2021 12:11

TRADING UPDATES: Princess exits Taco Bell; Nuformix files patent

TRADING UPDATES: Princess exits Taco Bell; Nuformix files patent

Read more
12 Nov 2021 10:54

SMALL-CAP WINNERS & LOSERS: Avon Protection plates face approval delay

SMALL-CAP WINNERS & LOSERS: Avon Protection plates face approval delay

Read more
9 Nov 2021 15:30

CORRECT: Nuformix Chair Alastair Riddell to move to executive chair

CORRECT: Nuformix Chair Alastair Riddell to move to executive chair

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.